Dopamine D2 Receptors(D2R) Imaging in Prolactinomas

• Status: Not yet recruiting
• Trial end date: 2022-01-31
• Target enrollment: 0
• Participant gender: All

Summary

To study the in vivo expression of dopamine D2 receptors in prolactinoma and the predictive role of dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhebao Wu
• Collaborators: Beijing Tiantan Hospital; Chinese PLA General Hospital; First Affiliated Hospital of Fujian Medical University; First Affiliated Hospital of Wenzhou Medical University; First Hospital of China Medical University; Huashan Hospital; Peking Union Medical College Hospital; Xinqiao Hospital of Chongqing
• Treatments: Dopamine; Dopamine Agents

Criteria

Inclusion Criteria:

1. Hyperprolactinemia;

2. Enhanced pituitary MRI shows sella regional tumor;

3. Aged between 18 and 65 years old, either sex;

4. Karnofsky performance status ≥ 70;

5. The patient has signed the informed consent.

Exclusion Criteria:

1. Patients concomitantly taking the psychotropic drugs or other drugs causing elevated PRL ;

2. Patients with parkinson disease and is taking dopaminergic agents;

3. Patients with prolactinoma who received Gamma knife treatment;

4. Pregnant or lactating women, or women preparing pregnant;

5. Patients with poor compliance, who cannot implement the program strictly.

6. History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabergoline.

7. Patients with claustrophobia